Eton Pharmaceuticals, Inc. (ETON) shares soared 13.8% in the last trading session to close at $42.32. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock’s 14.5% gain over the past four weeks.
The recent rally reflects growing investor confidence in the company’s long-term growth prospects, supported by the continued commercial momentum of marketed products such as Increlex, Hemangeol, Alkindi Sprinkle and Galzin, alongside its expanding rare disease portfolio. Investors also appear encouraged by the company’s late-stage pipeline — including Amglidia, ET-700, ET-800, and the Zeneo hydrocortisone autoinjector — which offers multiple potential catalysts for future growth, reinforcing expectations that ETON can sustain revenue expansion and further strengthen its commercial franchise.
This company is expected to post quarterly earnings of $0.13 per share in its upcoming report, which represents a year-over-year change of +230%. Revenues are expected to be $27.22 million, up 43.8% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Eton Pharmaceuticals, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock’s price usually doesn’t keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on ETON going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks Rank #1 (Strong Buy) stocks here >>>>
Eton Pharmaceuticals is a member of the Zacks Medical – Biomedical and Genetics industry. One other stock in the same industry, Celldex Therapeutics (CLDX), finished the last trading session 0.1% lower at $35.35. CLDX has returned 9.2% over the past month.
Celldex’s consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$1.04. Compared to the company’s year-ago EPS, this represents a change of -22.4%. Celldex currently boasts a Zacks Rank of #3 (Hold).
Radical New Technology Could Hand Investors Huge Gains
Quantum Computing is the next technological revolution, and it could be even more advanced than AI.
While some believed the technology was years away, it is already present and moving fast. Large hyperscalers, such as Microsoft, Google, Amazon, Oracle, and even Meta and Tesla, are scrambling to integrate quantum computing into their infrastructure.
Senior Stock Strategist Kevin Cook reveals 7 carefully selected stocks poised to dominate the quantum computing landscape in his report, Beyond AI: The Quantum Leap in Computing Power.
Kevin was among the early experts who recognized NVIDIA’s enormous potential back in 2016. Now, he has keyed in on what could be “the next big thing” in quantum computing supremacy. Today, you have a rare chance to position your portfolio at the forefront of this opportunity.
See Top Quantum Stocks Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Eton Pharmaceuticals, Inc. (ETON) : Free Stock Analysis Report
Celldex Therapeutics, Inc. (CLDX) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
